{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:49:09Z","timestamp":1791582549278,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-tongshu2021\/qn-0217"],"award-info":[{"award-number":["Y-tongshu2021\/qn-0217"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-HH202102-0365"],"award-info":[{"award-number":["Y-HH202102-0365"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["22ZR1438300"],"award-info":[{"award-number":["22ZR1438300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04428-6","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T08:13:51Z","timestamp":1779437631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TGF-\u03b2 inhibition enhances anti-tumor immunity and sensitizes PD-1 blockade therapy of bone marrow-derived myofibroblasts-induced \u201cimmunotherapy resistance\u201d tumor model"],"prefix":"10.1007","volume":"75","author":[{"given":"Xin","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiping","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"7","key":"4428_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","volume":"156","author":"AM Filho","year":"2025","unstructured":"Filho AM et al (2025) The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer 156(7):1336\u20131346","journal-title":"Int J Cancer"},{"key":"4428_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01953-7","author":"Q Li","year":"2024","unstructured":"Li Q et al (2024) Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-024-01953-7","journal-title":"Signal Transduct Target Ther"},{"issue":"10207","key":"4428_CR3","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E et al (2019) Colorectal cancer. Lancet 394(10207):1467\u20131480","journal-title":"Lancet"},{"issue":"2","key":"4428_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"issue":"26","key":"4428_CR5","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517\u20132526","journal-title":"N Engl J Med"},{"key":"4428_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01294-4","author":"J Weng","year":"2022","unstructured":"Weng J et al (2022) Exploring immunotherapy in colorectal cancer. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-022-01294-4","journal-title":"J Hematol Oncol"},{"issue":"7","key":"4428_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","volume":"3","author":"D Lavie","year":"2022","unstructured":"Lavie D et al (2022) Cancer-associated fibroblasts in the single-cell era. Nat Cancer 3(7):793\u2013807","journal-title":"Nat Cancer"},{"issue":"5","key":"4428_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1053\/j.gastro.2016.11.049","volume":"152","author":"V Koliaraki","year":"2017","unstructured":"Koliaraki V et al (2017) Mesenchymal cells in colon cancer. Gastroenterology 152(5):964\u2013979","journal-title":"Gastroenterology"},{"key":"4428_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.addr.2015.07.007","volume":"99","author":"G Ishii","year":"2016","unstructured":"Ishii G, Ochiai A, Neri S (2016) Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev 99:186\u2013196","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"4428_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41568-024-00740-4","volume":"24","author":"L Arpinati","year":"2024","unstructured":"Arpinati L, Carradori G, Scherz-Shouval R (2024) CAF-induced physical constraints controlling T cell state and localization in solid tumours. Nat Rev Cancer 24(10):676\u2013693","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4428_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","volume":"19","author":"M Quante","year":"2011","unstructured":"Quante M et al (2011) Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19(2):257\u2013272","journal-title":"Cancer Cell"},{"issue":"10","key":"4428_CR12","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/ijc.23925","volume":"123","author":"O De Wever","year":"2008","unstructured":"De Wever O et al (2008) Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123(10):2229\u20132238","journal-title":"Int J Cancer"},{"issue":"2","key":"4428_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/pmic.201200179","volume":"13","author":"A De Boeck","year":"2013","unstructured":"De Boeck A et al (2013) Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics 13(2):379\u2013388","journal-title":"Proteomics"},{"issue":"6","key":"4428_CR14","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ijc.20969","volume":"115","author":"T Sangai","year":"2005","unstructured":"Sangai T et al (2005) Effect of differences in cancer cells and tumor growth sites on recruiting bone marrow-derived endothelial cells and myofibroblasts in cancer-induced stroma. Int J Cancer 115(6):885\u2013892","journal-title":"Int J Cancer"},{"issue":"2","key":"4428_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s10120-014-0380-0","volume":"18","author":"S Terai","year":"2014","unstructured":"Terai S et al (2014) Bone marrow derived \u201cfibrocytes\u201d contribute to tumor proliferation and fibrosis in gastric cancer. Gastric Cancer 18(2):306\u2013313","journal-title":"Gastric Cancer"},{"key":"4428_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","author":"D Peng","year":"2022","unstructured":"Peng D et al (2022) Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer. https:\/\/doi.org\/10.1186\/s12943-022-01569-x","journal-title":"Mol Cancer"},{"issue":"3","key":"4428_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s12276-022-00742-y","volume":"54","author":"M Vukoti\u0107","year":"2022","unstructured":"Vukoti\u0107 M et al (2022) Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms. Exp Mol Med 54(3):273\u2013284","journal-title":"Exp Mol Med"},{"issue":"3","key":"4428_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D et al (2017) Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214(3):579\u2013596","journal-title":"J Exp Med"},{"issue":"4","key":"4428_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J (2019) Transforming Growth Factor-\u03b2 signaling in immunity and cancer. Immunity 50(4):924\u2013940","journal-title":"Immunity"},{"issue":"7693","key":"4428_CR20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF et al (2018) TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554(7693):538\u2013543","journal-title":"Nature"},{"issue":"7693","key":"4428_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544\u2013548","journal-title":"Nature"},{"issue":"5","key":"4428_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","volume":"8","author":"DA Thomas","year":"2005","unstructured":"Thomas DA, Massagu\u00e9 J (2005) TGF-\u03b2 directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8(5):369\u2013380","journal-title":"Cancer Cell"},{"issue":"1","key":"4428_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2013.09.017","volume":"343","author":"L Zhu","year":"2014","unstructured":"Zhu L et al (2014) Bone marrow-derived myofibroblasts promote colon tumorigenesis through the IL-6\/JAK2\/STAT3 pathway. Cancer Lett 343(1):80\u201389","journal-title":"Cancer Lett"},{"key":"4428_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09020-8","author":"J Shi","year":"2017","unstructured":"Shi J et al (2017) Targeted blockade of TGF-\u03b2 and IL-6\/JAK2\/STAT3 pathways inhibits lung cancer growth promoted by bone marrow-derived myofibroblasts. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-017-09020-8","journal-title":"Sci Rep"},{"key":"4428_CR25","doi-asserted-by":"publisher","first-page":"10567","DOI":"10.2147\/OTT.S266506","volume":"13","author":"J Wang","year":"2020","unstructured":"Wang J et al (2020) Bone marrow-derived myofibroblasts promote gastric cancer metastasis by activating TGF-\u03b21 and IL-6\/STAT3 signalling loop. Onco Targets Ther 13:10567\u201310580","journal-title":"Onco Targets Ther"},{"issue":"41","key":"4428_CR26","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1038\/onc.2016.76","volume":"35","author":"L Zhu","year":"2016","unstructured":"Zhu L et al (2016) Crosstalk between bone marrow-derived myofibroblasts and gastric cancer cells regulates cancer stemness and promotes tumorigenesis. Oncogene 35(41):5388\u20135399","journal-title":"Oncogene"},{"key":"4428_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619209","author":"T Huang","year":"2021","unstructured":"Huang T et al (2021) Wnt inhibition sensitizes PD-L1 blockade therapy by overcoming bone marrow-derived myofibroblasts-mediated immune resistance in tumors. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.619209","journal-title":"Front Immunol"},{"issue":"3","key":"4428_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S (2023) Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41(3):450\u2013465","journal-title":"Cancer Cell"},{"issue":"1","key":"4428_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, Sakaguchi S (2016) Regulatory T cells in cancer immunotherapy. Cell Res 27(1):109\u2013118","journal-title":"Cell Res"},{"issue":"1","key":"4428_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ (2019) CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol 37(1):457\u2013495","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"4428_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2021","unstructured":"Philip M, Schietinger A (2021) CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol 22(4):209\u2013223","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"4428_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU et al (2019) Defining \u2018T cell exhaustion.\u2019 Nat Rev Immunol 19(11):665\u2013674","journal-title":"Nat Rev Immunol"},{"issue":"W1","key":"4428_CR33","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z et al (2019) GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 47(W1):W556\u2013W560","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"4428_CR34","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1093\/bioinformatics\/bty411","volume":"34","author":"CJ Liu","year":"2018","unstructured":"Liu CJ et al (2018) GSCALite: a web server for gene set cancer analysis. Bioinformatics 34(21):3771\u20133772","journal-title":"Bioinformatics"},{"issue":"5","key":"4428_CR35","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/2326-6066.CIR-23-0903","volume":"13","author":"S Wang","year":"2025","unstructured":"Wang S et al (2025) A bifunctional antibody targeting PD-1 and TGF-\u03b2 signaling has antitumor activity in combination with radiotherapy and attenuates radiation-induced lung injury. Cancer Immunol Res 13(5):767\u2013784","journal-title":"Cancer Immunol Res"},{"issue":"7832","key":"4428_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41586-020-2850-3","volume":"587","author":"S Li","year":"2020","unstructured":"Li S et al (2020) Cancer immunotherapy via targeted TGF-\u03b2 signalling blockade in TH cells. Nature 587(7832):121\u2013125","journal-title":"Nature"},{"issue":"1","key":"4428_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/cac2.12244","volume":"42","author":"B Cheng","year":"2022","unstructured":"Cheng B et al (2022) Anti-PD-L1\/TGF-\u03b2R fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1\/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond) 42(1):17\u201336","journal-title":"Cancer Commun (Lond)"},{"key":"4428_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488","author":"Y Lan","year":"2018","unstructured":"Lan Y et al (2018) Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aan5488","journal-title":"Sci Transl Med"},{"issue":"6","key":"4428_CR39","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","volume":"24","author":"J Strauss","year":"2018","unstructured":"Strauss J et al (2018) Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2. Adv Solid Tumors Clin Cancer Res 24(6):1287\u20131295","journal-title":"Adv Solid Tumors Clin Cancer Res"},{"issue":"1","key":"4428_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41392-024-02063-0","volume":"9","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ et al (2024) Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer. Signal Transduct Target Ther 9(1):349","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4428_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M et al (2021) The construction, expression, and enhanced anti-tumor activity of YM101: A bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1. J Hematol Oncol 14(1):27","journal-title":"J Hematol Oncol"},{"key":"4428_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111698","author":"W Fan","year":"2024","unstructured":"Fan W et al (2024) An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-\u03b2 with enhanced antitumor efficacies. Int Immunopharmacol. https:\/\/doi.org\/10.1016\/j.intimp.2024.111698","journal-title":"Int Immunopharmacol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04428-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:37:15Z","timestamp":1784684235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04428-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4428"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04428-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"190"}}